Evaluation of the efficacy of atorvastatin calcium tablets in the treatment of patients with pulmonary hypertension caused by pulmonary diseases

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400093265

Enrollment

Unknown

Registered

2024-12-01

Start date

2024-12-01

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary hypertension due to lung disease

Interventions

Pulmonary arterial hypertension due to chronic obstructive pulmonary disease experimental group:Conventional treatment + atorvastatin calcium tablets

Pulmonary arterial hypertension due to chronic obstructive pulmonary disease control group:Conventional treatment

Pulmonary hypertension due to interstitial lung disease experimental group:Conventional treatment + atorvastatin calcium tablets

Pulmonary hypertension due to interstitial lung disease control group:Conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Incorporate criteria: 1. Age between 18 and 80 years old. 2. Diagnosis of pulmonary arterial hypertension due to lung disease, with specific diagnostic criteria: (1) Confirmed by right heart catheterization, mean pulmonary artery pressure (mPAP) >= 25 mmHg. (2) Pulmonary artery wedge pressure (PAWP) <= 15 mmHg. (3) Clear history of lung disease, such as chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). 3. Agree to participate in this study and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Pregnant or lactating women. 2. Severe liver or kidney dysfunction, or other life-threatening complications. 3. Recently (within the past 3 months) received unapproved new drug treatments. 4. Known allergy to atorvastatin calcium tablets. 5. Patients taking cyclosporine, gemfibrozil, clarithromycin, antiviral drugs, macrolide antibiotics, or antifungal drugs. 6. Patients with low blood lipid levels (LDL < 1.0 mmol/L). 7. Poor compliance or inability to complete study follow-up on time. 8. Pulmonary arterial hypertension caused by other reasons.

Design outcomes

Primary

Measure	Time frame
Six-minute walk distance;	—

Secondary

Measure	Time frame
A right heart catheterization measures pulmonary artery pressure;Echocardiography;NT-proBNP;Liver function;Renal function.;	—

Countries

China

Contacts

Public ContactFan Ye

The Second Affiliated Hospital of Army Military Medical University

fygan@163.com+86 180 0233 5652

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026